Vivos Therapeutics, Inc. entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock at a purchase price of $4.08 per share for gross proceeds of $4,000,003.44 on October 30, 2023. In addition, the company will issue to the investor a five year Series A Warrant to purchase up to an aggregate of 980,393 shares of common stock and an eighteen month Series B Warrant to purchase up to an aggregate of 980,393 shares of common stock. The Series A and Series B Warrants will have an exercise price of $3.83 per share and will be exercisable immediately following the date of issuance.

The closing of the private placement is expected to occur on or about November 2, 2023. After deducting the placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $3.5 million.